- Home
- OP vs FEMY Comparison
OP vs FEMY Comparison
Compare OP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- FEMY
- Stock Information
- Founded
- OP 2021
- FEMY 2004
- Country
- OP Greece
- FEMY United States
- Employees
- OP N/A
- FEMY N/A
- Industry
- OP
- FEMY Medical/Dental Instruments
- Sector
- OP
- FEMY Health Care
- Exchange
- OP Nasdaq
- FEMY Nasdaq
- Market Cap
- OP 14.3M
- FEMY 12.5M
- IPO Year
- OP N/A
- FEMY 2021
- Fundamental
- Price
- OP $1.24
- FEMY $0.39
- Analyst Decision
- OP
- FEMY Strong Buy
- Analyst Count
- OP 0
- FEMY 3
- Target Price
- OP N/A
- FEMY $7.33
- AVG Volume (30 Days)
- OP 1.2M
- FEMY 2.8M
- Earning Date
- OP 12-02-2025
- FEMY 11-11-2025
- Dividend Yield
- OP N/A
- FEMY N/A
- EPS Growth
- OP N/A
- FEMY N/A
- EPS
- OP N/A
- FEMY N/A
- Revenue
- OP $19,435,000.00
- FEMY $1,887,016.00
- Revenue This Year
- OP N/A
- FEMY $103.55
- Revenue Next Year
- OP N/A
- FEMY $148.13
- P/E Ratio
- OP N/A
- FEMY N/A
- Revenue Growth
- OP N/A
- FEMY 98.61
- 52 Week Low
- OP $1.07
- FEMY $0.31
- 52 Week High
- OP $79.25
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- OP 32.18
- FEMY 31.02
- Support Level
- OP $1.07
- FEMY $0.35
- Resistance Level
- OP $1.21
- FEMY $0.57
- Average True Range (ATR)
- OP 0.12
- FEMY 0.05
- MACD
- OP 0.76
- FEMY 0.01
- Stochastic Oscillator
- OP 25.37
- FEMY 29.11
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.